RESUMO
A strategy to conformationally restrain a series of GlyT1 inhibitors identified potent analogs that exhibited slowly interconverting rotational isomers. Further studies to address this concern led to a series of azetidine-based inhibitors. Compound 26 was able to elevate CSF glycine levels in vivo and demonstrated potency comparable to Bitopertin in an in vivo rat receptor occupancy study. Compound 26 was subsequently shown to enhance memory in a Novel Object Recognition (NOR) behavioral study after a single dose of 0.03 mg/kg, and in a contextual fear conditioning (cFC) study after four QD doses of 0.01-0.03 mg/kg.
Assuntos
Azetidinas/farmacologia , Proteínas da Membrana Plasmática de Transporte de Glicina/antagonistas & inibidores , Memória/efeitos dos fármacos , Azetidinas/síntese química , Azetidinas/química , Relação Dose-Resposta a Droga , Células HEK293 , Humanos , Estrutura Molecular , Relação Estrutura-AtividadeRESUMO
We report here the identification and optimization of a novel series of potent GlyT1 inhibitors. A ligand design campaign that utilized known GlyT1 inhibitors as starting points led to the identification of a novel series of pyrrolo[3,4- c]pyrazoles amides (21-50) with good in vitro potency. Subsequent optimization of physicochemical and in vitro ADME properties produced several compounds with promising pharmacokinetic profiles. In vivo inhibition of GlyT1 was demonstrated for select compounds within this series by measuring the elevation of glycine in the cerebrospinal fluid (CSF) of rats after a single oral dose of 10 mg/kg. Ultimately, an optimized lead, compound 46, demonstrated in vivo efficacy in a rat novel object recognition (NOR) assay after oral dosing at 0.1, 1, and 3 mg/kg.
Assuntos
Desenho de Fármacos , Proteínas da Membrana Plasmática de Transporte de Glicina/antagonistas & inibidores , Memória/efeitos dos fármacos , Pirazóis/síntese química , Pirazóis/farmacologia , Animais , Técnicas de Química Sintética , Proteínas da Membrana Plasmática de Transporte de Glicina/química , Proteínas da Membrana Plasmática de Transporte de Glicina/metabolismo , Células HEK293 , Humanos , Modelos Moleculares , Conformação Molecular , Permeabilidade , Pirazóis/química , Pirazóis/metabolismo , RatosRESUMO
The synthesis and characterization of several Cr(III) complexes of the constrained macrocyclic ligand 1,4-C(2)-cyclam = 1,4,8,11-tetraazabicyclo[10.2.2]hexadecane is reported. The ligand appears to form only trans complexes, and the structure of trans-[Cr(1,4-C(2)-cyclam)Cl(2)]PF(6) is presented. The constraint imposed by the additional C(2) linkage distorts the bond angles significantly away from the ideal values of 90 and 180 degrees. The effect of the distortion is to enhance the aquation rate of trans-[Cr(1,4-C(2)-cyclam)Cl(2)](+) (k(obs) for trans-[Cr(1,4-C(2)-cyclam)(H(2)O)(2)](3+) formation = 6.5 x 10(-)(2) s(-)(1), 0.01M HNO(3), 25 degrees C) by over 5 orders of magnitude relative to trans-[Cr(cyclam)Cl(2)](+). The complexes trans-[Cr(1,4-C(2)-cyclam)Cl(2)](+) and trans-[Cr(1,4-C(2)-cyclam)(CN)(2)](+) are found to have extinction coefficients four to five times higher than their cyclam analogues, owed to the lack of centrosymmetry caused by the steric constraint. The trans-[Cr(1,4-C(2)-cyclam)(CN)(2)](+) complex is a very weak emitter in aqueous solution with a broad room-temperature emission centered at 735 nm (tau = 0.24 micros). Extended photolysis (350 nm, 15 h) of trans-[Cr(1,4-C(2)-cyclam)(CN)(2)](+) in aqueous solution results in CN(-) ligand loss. This is in stark contrast to its unconstrained cyclam analogue, which is photoinert and has a room-temperature emission lifetime of 335 micros.
